Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study.

• Tác giả: Amira Alkourdi, Joana Amengual, Octavio Arencibia, Leticia Azcona, Monica Bellon, Ana Boldo, Maria Nieves Cabezas, Laura Cardenas, Berta Diaz-Feijoo, Blanca Gil-Ibañez, Mikel Gorostidi, Marta Heras, Alicia Hernandez, Marta Lamarca, Arantxa Lekuona, Lola Marti, Lucas Minig, Isabel Niguez, Laia Ribot, Ignacio Zapardiel
• Ngôn ngữ: eng
• Ký hiệu phân loại: 978.02 1800–1899
• Thông tin xuất bản: United States : International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics , 2025
• Bộ sưu tập: NCBI
• ID: 715626

Tóm tắt

 OBJECTIVE: To assess the safety of fertility-sparing treatments for early-stage ovarian cancer in women younger than 40 years old. METHODS: We performed a retrospective multicenter study including women aged 18-40 years diagnosed with early-stage (FIGO I-II) ovarian cancer in 55 Spanish hospitals, from January 2010 to December 2019. Benign and borderline tumors were excluded, as well as advanced stages (FIGO III-IV). All perioperative characteristics and follow-up data were collected and analyzed. Standard staging surgery (SSS) was compared with fertility-sparing surgery (FSS) in terms of oncological outcomes. RESULTS: In all, 366 women were included
  327 (89.3%) were stage I. Among all patients, 216 (59%) underwent SSS and 150 (41%) FSS. Up to 208 (56.8%) patients did not have children, but only 12 (3.2%) had oocyte preservation before treatment. Patients in the FSS group compared with the SSS group showed a non-significant difference in recurrences (8% vs. 9.3%, respectively
  P <
  0.711) and deaths (1.3% vs. 4.8%, respectively
  P = 0.211) during the follow-up. No significant differences were found between epithelial and non-epithelial ovarian cancer both in recurrences (7.1% vs. 8.8%, respectively
  P = 0.771) and in deaths (1.4% vs. 1.3%, respectively
  P = 1) among patients who underwent FSS. CONCLUSION: FSS seems a safe option for treatment of early-stage ovarian cancer in patients who want to preserve fertility, either for epithelial and non-epithelial histology.